Xu Wang

Xu Wang

Auto-generated profile, based on publicly available information

Xu Wang

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2021 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
BLBaohua Liu
Baohua Liu
JRJing Ruan
Jing Ruan
MCMeng Chen
Meng Chen
ZLZhongding Li
Zhongding Li
GMGloria Manjengwa
Gloria Manjengwa
XWXu Wang
Xu Wang

1 June 2021 in Molecular Therapy
Verified
Journal Article
Open access
JRJing Ruan
Jing Ruan
XMXiaomin Miao
Xiaomin Miao
DSDirk Schlüter
Dirk Schlüter
LLLi Lin
Li Lin
XWXu Wang
Xu Wang
Extracellular vesicles (EVs) are bilayer membrane vesicles and act as key messengers in intercellular communication. EVs can be secreted by both neurons and glial cells in the central nervous system (CNS). Under physiological conditions, EVs contribute to the CNS homeostasis by facilitating omnidirectional communication among CNS cell populations. In response to CNS injury, EVs mediate neuroinflammatory responses and regulate tissue damage and repair, thereby influencing the pathogenesis, development, and/or recovery of neuroinflammatory diseases including CNS autoimmune diseases, neurodegenerative diseases, stroke, CNS traumatic injury, and CNS infectious diseases. The unique ability of EVs to pass through the blood brain barrier further confers them an important role in the bidirectional communication between the CNS and periphery, and application of EVs enables the diagnosis, prognosis, and therapy of neuroinflammatory diseases in a minimally invasive manner.

5 February 2020 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
FMFloriana Mulas
Floriana Mulas
XWXu Wang
Xu Wang
SSShanshan Song
Shanshan Song
GNGopala Nishanth
Gopala Nishanth
WYWenjing Yi
Wenjing Yi
DSDirk Schlüter
Dirk Schlüter
Dendritic cells (DCs) are indispensable for defense against pathogens but may also contribute to immunopathology. Activation of DCs upon the sensing of pathogens by Toll-like receptors (TLRs) is largely mediated by pattern recognition receptor/nuclear factor-κB (NF-κB) signaling and depends on the appropriate ubiquitination of the respective signaling molecules. However, the ubiquitinating and deubiquitinating enzymes involved and their interactions are only incompletely understood. Here, we reveal that the deubiquitinase OTU domain, ubiquitin aldehyde binding 1 (OTUB1) is upregulated in DCs upon murine Toxoplasmagondii infection and lipopolysaccharide challenge. Stimulation of DCs with the TLR11/12 ligand T. gondii profilin and the TLR4 ligand lipopolysaccharide induced an increase in NF-κB activation in OTUB1-competent cells, resulting in elevated interleukin-6 (IL-6), IL-12, and tumor necrosis factor (TNF) production, which was also observed upon the specific stimulation of TLR2, TLR3, TLR7, and TLR9. Mechanistically, OTUB1 promoted NF-κB activity in DCs by K48-linked deubiquitination and stabilization of the E2-conjugating enzyme UBC13, resulting in increased K63-linked ubiquitination of IRAK1 (IL-1 receptor-associated kinase 1) and TRAF6 (TNF receptor-associated factor 6). Consequently, DC-specific deletion of OTUB1 impaired the production of cytokines, in particular IL-12, by DCs over the first 2 days of T. gondii infection, resulting in the diminished production of protective interferon-γ (IFN-γ) by natural killer cells, impaired control of parasite replication, and, finally, death from chronic T.encephalitis, all of which could be prevented by low-dose IL-12 treatment in the first 3 days of infection. In contrast, impaired OTUB1-deficient DC activation and cytokine production by OTUB1-deficient DCs protected mice from lipopolysaccharide-induced immunopathology. Collectively, these findings identify OTUB1 as a potent novel regulator of DCs during infectious and inflammatory diseases.

1 March 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
QZQiuyang Zheng
Qiuyang Zheng
BSBeibei Song
Beibei Song
GLGuilin Li
Guilin Li
FCFang Cai
Fang Cai
MWMeiling Wu
Meiling Wu
XWXin Wang
Xin Wang
Down syndrome (DS), or trisomy 21, is one of the critical risk factors for early-onset Alzheimer’s disease (AD), implicating key roles for chromosome 21–encoded genes in the pathogenesis of AD. We previously identified a role for the deubiquitinase USP25, encoded on chromosome 21, in regulating microglial homeostasis in the AD brain; however, whether USP25 affects amyloid pathology remains unknown. Here, by crossing 5×FAD AD and Dp16 DS mice, we observed that trisomy 21 exacerbated amyloid pathology in the 5×FAD brain. Moreover, bacterial artificial chromosome (BAC) transgene–mediated USP25 overexpression increased amyloid deposition in the 5×FAD mouse brain, whereas genetic deletion of Usp25 reduced amyloid deposition. Furthermore, our results demonstrate that USP25 promoted β cleavage of APP and Aβ generation by reducing the ubiquitination and lysosomal degradation of both APP and BACE1. Importantly, pharmacological inhibition of USP25 ameliorated amyloid pathology in the 5×FAD mouse brain. In summary, we identified the DS-related gene USP25 as a critical regulator of AD pathology, and our data suggest that USP25 serves as a potential pharmacological target for AD drug development.

1 August 2019 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
WYWenjing Yi
Wenjing Yi
DSDirk Schlüter
Dirk Schlüter
XWXu Wang
Xu Wang

15 February 2022 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
JRJing Ruan
Jing Ruan
DSDirk Schlüter
Dirk Schlüter
MNMichael Naumann
Michael Naumann
AWAri Waisman
Ari Waisman
XWXu Wang
Xu Wang